drugset / Trial / NCT00352742

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

NCT00352742

Phase 1/2 Terminated 46 enrolled Attenuon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.

Timeline

Start
2006-06
Primary completion
2008-09
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TIOMOLIBDATE CHOLINE Small molecule
Background Bortezomib Small molecule

Indications